Abstract
We defined the pharmacokinetics of paclitaxel after i. v., i. p., p. o., and s. c. administration of 22.5 mg/kg to CD2F1 mice. Additional mice were studied after i. v. bolus dosing at 11.25 mg/kg or 3-h continuous i.v. infusions delivered at 43.24 μg kg−1 min−1. Plasma was sampled between 5 min and 40 h after dosing. Brains, hearts, lungs, livers, kidneys, skeletal muscles, and, where applicable, testicles were sampled after i.v. dosing at 22.5 mg/kg. Liquid-liquid extraction followed by isocratic high-performance liquid chromatography (HPLC) with UV detection was used to determine paclitaxel concentrations in plasma and tissues. After i.v. administration to male mice, paclitaxel clearance (CLtb) was 3.25 ml min−1 kg−1 and the terminal half-life (t 1/2) was 69 min. After i.v. administration to female mice, paclitaxel CLtb was 4.54 ml min−1 kg−1 and the terminalt1/2 was 43 min. The bioavailability of paclitaxel was ∼10%, 0, and 0 after i.p., p.o., and s.c. administration, respectively. Paclitaxel bioavailability after i.p. administration was the same when the drug was delivered in a small volume to mimic the delivery method used to evaluate in vivo antitumor efficacy or when it was delivered in a large volume to simulate clinical protocols using i.p. regional therapy. Paclitaxel was not detected in the plasma of mice after i.p. delivery of the drug as a suspension in Klucel: Tween 80. Pharmacokinetic parameters were similar after i.v. delivery of paclitaxel at 22.5 and 11.25 mg/kg; however, the CLtb calculated in these studies was much lower than that associated with 3-h continuous i.v. infusions. After i.v. administration, paclitaxel was distributed extensively to all tissues but the brain and testicle. These data are useful in interpreting preclinical efficacy studies of paclitaxel and predicting human pharmacokinetics through scaling techniques.
Similar content being viewed by others
References
Chang A, Kim K, Glick J, Anderson T, Karp D, Johnson D (1993) Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer; the Eastern Cooperative Oncology Group (ECOG) results. J Natl Cancer Inst 85: 388
Collins JM, Zaharko DS, Dedrick RL, Chabner BA (1986) Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 70: 73
Collins JM, Grieshaber CK, Chabner BA (1990) Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst 82: 1321
D'Argenio DZ, Schumitzky A (1979) A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Methods Programs Biomed 9: 115
Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS (1987) Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 71: 1171
Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL (1992) Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10: 1748
Ettinger DS, Finklestein DM, Sarma R, Johnson DH (1993) Phase II study of taxol in patients with extensive small cell lung cancer. Proc Am Soc Clin Oncol 12: 329
Forastiere AA, Neuberg D, Taylor SG IV, DeConti R, Adams G (1993) Phase II evaluation of taxol in advanced head and neck cancer. Proc Am Soc Clin Oncol 12: 277
Francis P, Rowinsky E, Hakes T, Schneider J, Barakat R, Curtin J, Jones W, Lewis J Jr, Rubin S, Dunlap V, Phillips M, Almadrones L, Hoskins W, Markman M (1993) Phase I trial of weekly intraperitoneal (ip) taxol in patients (pts) with residual ovarian carcinoma (OC): a GOG study. Proc Am Soc Clin Oncol 12: 257
Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN (1991) Phase II trial of taxol, an active drug in metastatic breast cancer. J Natl Cancer Inst 83: 1797
Investigational Drug Branch, National Cancer Institute (1990) Taxol (NSC 125973) Clinical Brochure. National Cancer Institute, Bethesda, Maryland
Jamis-Dow CA, Klecker RW, Sarosy GA, Reed E, Collins JM (1993) Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 33: 48
Kearns C, Gianni L, Vigano L, Giani A, Spriggs D, Tutsch K, Schiller J, Sridhara R, Egorin M (1993) Non-linear pharmacokinetics of taxol in humans. Proc Am Soc Clin Oncol 12: 135
Keung ACF, Kaul S, Pinedo HM, Ten Bokkel-Huinink WW, Beijnen JH (1993) Pharmacokinetics of taxol given by 3-h or 24-h infusion to patients with ovarian carcinoma. Proc Am Soc Clin Oncol 12: 130
Klecker RW, Jamis-Dow CA, Egorin MJ, Erkmen K, Parker RJ, Stevens R, Collins JM (1994) Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion and metabolism of3H-taxol in the Sprague-Dawley rat. Drug Metab Dispos 22: 254
Kris MG, O'Connell JP, Gralla RJ (1986) Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 70: 605
Kumar N (1981) Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 256: 10435
Legha SS, Ring S, Papadouplos N (1990) A phase II trial of taxol in metastatic melanoma. Cancer 65: 2478
Leslie J, Kujawa JM, Eddington N, Egorin M, Eiseman J (1993) Stability problems with taxol in mouse plasma during HPLC analysis. J Pharm Biomed Anal 11: 1349
Manfredi JJ, Horwitz SB (1984) An antimitotic agent with a new mechanism of action. Pharmacol Ther 25: 83
Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr, Rubin S, Curtin J, Barakat R, Phillips M, Horwotz L, Almadrones L, Hoskins W (1992) Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J Clin Oncol 10: 1485
McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC (1989) A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111: 273
Monsarrat B, Mariel E, Cros S, Gares D, Guénard D, Guéritte-Voegelein F, Wright M (1990) Taxol metabolism. Isolation and identification of three major metabolites of taxol in rat bile. Drug Metab Dispos 18: 895
Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN, Krakoff IH, Hong WK (1993) Phase II study of taxol in patients with untreated non-small cell lung cancer. J Natl Cancer Inst 85: 384
Reichman BS, Seidman AD, Crown JPA, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, Hudis CA, Yao TJ, Klecker R, Jamis-Dow C, Collins J, Quinlivan S, Berkery R, Toomasi F, Canetta R, Fisherman J, Arbuck S, Norton L (1993) Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11: 1943
Rocci ML, Jusko WJ (1983) LAGRAN program for area and moments in pharmacokinetic analysis. Comput Methods Programs Biomed 16: 203
Rowinsky EK, Burke PJ, Karp JE, Tucker RW, Ettinger DS, Donehower RC (1989) Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res 49: 4640
Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247
Rowinsky EK, Gilbert M, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE, Cornblath DR, Hendricks CB, Donehower RC (1991) Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9: 1692
Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejki BG, Cornblath DR, Donehower RC (1993) Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 11: 2010
Sarosy G, Kohn E, Stone DA, Rothenberg M, Jacob J, Adamo DO, Ognibene FP, Cunnion RE, Reed E (1992) Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10: 1165
Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277: 665
Sonnichsen D, Hurwitz C, Pratt C, Relling M (1993) Clinical pharmacodynamics and saturable pharmacokinetics of taxol in pediatric solid tumor patients. Proc Am Soc Clin Oncol 12: 133
Swenerton K, Eisenhauer E, Bokkel Huinink W ten, Myles J, Mangioni C, Burg M van der, Kerr I, Gianni L, Vermorken J, Buser K, Sadura A, Bacon M, Santabarbara P, Onetto N, Canetta R (1993) Taxol in relapsed ovarian cancer: high vs low dose and short vs long infusion: a European-Canadian study coordinated by the NCI Canada Clinical Trials Group. Proc Am Soc Clin Oncol 12: 256
Thigpen T, Blessing J, Ball H, Hummel S, Barret R (1990) Phase II trial of taxol as second-line therapy for ovarian carcinoma: a Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 9: 156
Wall ME, Wani MC (1977) Antineoplastic agents from plants. Annu Rev Pharmacol Toxicol 17: 117
Walle T, Kumar GN, McMillan JM, Thornburg KR, Walle UK (1994) Taxol metabolism in rat hepatocytes. Biochem Pharmacol (in press)
Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent fromTaxus brevifolia. J Am Chem Soc 93: 2325
Wiernik PH, Schwartz EL, Einzig A (1987) Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 5: 1232
Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E (1987) Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47: 2486
Yeh KC, Kwan KC (1978) A comparison of numerical integrating algorithms by trapezoidal, LaGrange and Spline approximation. J Pharmacokinet Biopharm 6: 79
Author information
Authors and Affiliations
Additional information
This work was supported by contract NO1-CM27711 awarded by the National Cancer Institute, DHHS
Rights and permissions
About this article
Cite this article
Eiseman, J.L., Eddington, N.D., Leslie, J. et al. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother. Pharmacol. 34, 465–471 (1994). https://doi.org/10.1007/BF00685656
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685656